Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVERLORD-MS
2024-510716-71-00Phase 3Authorised
- Sponsor
- Helse Bergen
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in multiple sclerosis (MS) comparing Ocrevus arm with MabThera arm (2 arms). Planned start Oct 2020; status: authorised.
02
Drugs
ocrelizumabrituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-510716-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510716-71-00.